EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• TYENNE (TOCILIZUMAB-AAZG)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Cytokine Release Syndrome;Arthritis, Juvenile Rheumatoid;COVID-19 virus infection;Giant Cell Arteritis. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 02/10/2025